CLRB Cellectar Biosciences

Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update

Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update

FLORHAM PARK, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2019 and provided a corporate update.

Fourth Quarter and Recent Corporate Highlights

  • Announced CLR 131 achieved primary efficacy endpoints from its Phase 2 CLOVER-1 study in relapsed/refractory B-cell lymphomas and completion of the Phase 1 relapsed/refractory multiple myeloma Dose Escalation study. The data showed:



    ○  42.8% overall response rate (ORR) in median 6th line treatment of multiple myeloma at the 75mCi total body dose

     

    ○  81.8% of the multiple myeloma patients across all therapeutic doses tested experienced tumor reduction with a strong dose response

     

    ○  100% ORR and 25% complete response (CR) seen in lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia (LPL/WM) patients

     

    ○  42.0% ORR and 11% CR in all non-Hodgkin’s lymphoma (NHL) patients

     
  • Received Orphan Drug Designation for CLR 131 in lymphoplasmacytic lymphoma (LPL) from the U.S. Food and Drug Administration

     
  • Oral presentation at the American Society of Hematology (ASH) Conference entitled

     
  • Oral presentation at the European Society of Medical Oncology (ESMO) Congress entitled

     
  • Scientific conference poster presentations during the quarter included:

    ○  American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium entitled

    ○  AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference entitled



    ○  UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology entitled

     
  • Strengthened the management team with the appointment of Dr. Igor Grachev, Chief Medical Officer

“Data from our CLR 131 Phase 1 dose escalation study and the Phase 2 CLOVER-1 study demonstrated a unique safety profile and an encouraging response rate of nearly 43% as a sixth-line treatment for relapsed/refractory multiple myeloma,” said James Caruso, President and CEO of Cellectar. “Importantly, the 75mCi dose demonstrated excellent activity in very challenging to treat subpopulations, high-risk, triple class refractory and penta-refractory. We plan to enroll additional patients at 100mCi of CLR 131 in the two-cycle dosing optimization regimen, which we believe will further increase response rates, the durability of responses and will likely be used in our pivotal study planned for initiation in Q4 of this year.”

2019 Financial Highlights

Cash and Cash Equivalents: As of December 31, 2019, the company had cash, cash equivalents and restricted cash of $10.6 million compared to $13.3 million at December 31, 2018. Cash provided by financing activities was $9.0 million, offset by cash used in operating activities of $11.7 million. Consistent with prior guidance, the company believes its cash on hand is adequate to fund operations into the first quarter of 2021.

Research and Development Expense: Research and development expense for the year ended December 31, 2019 was $9.0 million, compared to $6.8 million for the year ended December 31, 2018. The overall increase in research and development expense of approximately 32% was primarily attributable to an increase in clinical project costs largely related to the startup of the pediatric study, as well as an increase in patient recruitment for the ongoing clinical studies.

General and Administrative Expense: General and administrative expense for the year ended December 31, 2019 was $5.2 million, compared to $4.8 million for the year ended December 31, 2018. The increase of 8% in general and administrative costs was primarily related to an increase in personnel and consulting costs and an increase related to public company expenses, rent and depreciation. These costs were offset by a decrease in accounting fees and restructuring charges.

Net Loss: The net loss attributable to common stockholders for the year ended December 31, 2019 was ($14.1) million, or ($1.84) per share, compared to ($15.5) million, or ($5.23) per share, in 2018.

About Cellectar Biosciences, Inc.

Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.

The company’s lead PDC therapeutic, CLR 131, is currently in two clinical studies - one Phase 2 study and one Phase 1 study, having just completed their Phase 1 relapsed/refractory multiple myeloma Dose Escalation study. The Phase 2 clinical study (CLOVER-1) is in relapsed/refractory (r/r) B-cell malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia (LPL/WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). The company is also conducting a Phase 1 dose escalation study in patients with pediatric solid tumors and lymphomas.

The company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900) and several partnered PDC assets.

For more information, please visit or join the conversation by liking and following us on the company’s social media channels: , , and .

Forward-Looking Statement Disclaimer

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of CLR 131, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in the United States for CLR 131,the volatile market for priority review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2018 and our Form 10-K for the year ended December 31, 2019, when filed. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

Contacts

Investors:

Monique Kosse

Managing Director

LifeSci Advisors

646-915-3820

 
CELLECTAR BIOSCIENCES, INC.
 
CONSOLIDATED BALANCE SHEETS
       
  December 31,

2019
  December 31,

2018
 
ASSETS        
CURRENT ASSETS:        
Cash and cash equivalents $10,614,722  $13,255,616 
Restricted cash     55,000 
Prepaid expenses and other current assets  770,951   641,218 
Total current assets  11,385,673   13,951,834 
Fixed assets, net  435,083   543,339 
Right-of-use asset, net  348,841    
Long-term assets  75,000   540,823 
Other assets  6,214   18,086 
TOTAL ASSETS $12,250,811  $15,054,082 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
CURRENT LIABILITIES:        
Accounts payable and accrued liabilities $2,663,873  $1,543,819 
Derivative liability     43,000 
Capital lease obligations, current portion     2,213 
Deferred rent     33,090 
Lease liability  105,885    
Total current liabilities  2,769,758   1,622,122 
LONG-TERM LIABILITIES:        
Deferred rent, less current portion     170,999 
Lease liability  421,644    
Total long-term liabilities  421,644   170,999 
TOTAL LIABILITIES  3,191,402   1,793,121 
COMMITMENTS AND CONTINGENCIES (Note 11)        
STOCKHOLDERS’ EQUITY:        
Preferred stock, $0.00001 par value; 7,000 shares authorized; Series C preferred stock: 215 and 473 issued and outstanding as of December 31, 2019 and 2018, respectively  1,148,204   2,526,049 
Common stock, $0.00001 par value; 80,000,000 shares authorized; 9,386,689 and 4,732,387 shares issued and outstanding at December 31, 2019 and 2018, respectively  94   47 
Additional paid-in capital  119,592,366   108,323,208 
Accumulated deficit  (111,681,255)  (97,588,343)
Total stockholders’ equity  9,059,409   13,260,961 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $12,250,811  $15,054,082 
         



 
CELLECTAR BIOSCIENCES, INC.
 
CONSOLIDATED STATEMENTS OF OPERATIONS
    
  Year Ended December 31, 
  2019  2018 
       
COSTS AND EXPENSES:        
Research and development $8,996,058  $6,835,229 
General and administrative  5,182,566   4,820,073 
Impairment of goodwill     1,675,462 
Total costs and expenses  14,178,624   13,330,764 
         
LOSS FROM OPERATIONS  (14,178,624)  (13,330,764)
         
OTHER INCOME:        
Gain on revaluation of derivative warrants  43,000   62,050 
Interest income, net  42,712   29,687 
Total other income, net  85,712   91,737 
NET LOSS  (14,092,912)  (13,239,027)
DEEMED DIVIDEND ON PREFERRED STOCK     (2,241,795)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS  (14,092,912)  (15,480,822)
BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $(1.84) $(5.23)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE  7,675,092   2,961,972 
         

EN
09/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectar Biosciences

 PRESS RELEASE

Cellectar Biosciences Reports Financial Results for Year Ended 2023 an...

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update Management to host a conference call today at 8:30 am ET FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update. “2023 was a year of significant progress for Cellectar, culminating in the January...

 PRESS RELEASE

Cellectar Biosciences to Announce 2023 Year End Earnings Results and H...

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Management will also host a conference call with investors to discuss financial results and p...

 PRESS RELEASE

Cellectar Biosciences to Present at the 36th Annual Roth Conference

Cellectar Biosciences to Present at the 36th Annual Roth Conference FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jim Caruso, president and chief executive officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming 36th Annual Roth Conference taking place on March 17 to 19, 2024 in Laguna Niguel, CA. Details of the fireside chat are a...

 PRESS RELEASE

Cellectar Biosciences Reports High Rate of Complete Remission in Inves...

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer Complete Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients Durability of clinical activity achieved 67% Overall Survival and 42% Progression Free Survival at One Year FLORHAM PARK, N.J., March 04, 2024 (GLOBE NEWSWIRE) --  Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, dev...

 PRESS RELEASE

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Health...

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and chief executive officer of Cellectar, will present an overview of the company at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually. Details of the presentati...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch